$8.18
-0.06 (-0.73%)
Open$8.18
Previous Close$8.24
Day High$8.24
Day Low$7.92
52W High$42.79
52W Low$5.67
Volume—
Avg Volume22.4K
Market Cap56.70M
P/E Ratio—
EPS$-11.39
SectorBiotechnology
Analyst Ratings
Buy
8 analysts
Price Target
-1.8% upside
Current
$8.18
$8.18
Target
$8.03
$8.03
$5.28
$8.03 avg
$9.44
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 12.19M | 11.47M | 10.10M |
| Net Income | 876.0K | 905.7K | 740.1K |
| Profit Margin | 7.2% | 7.9% | 7.3% |
| EBITDA | 1.90M | 1.88M | 1.67M |
| Free Cash Flow | 486.5K | 519.3K | 559.1K |
| Rev Growth | +7.7% | +14.6% | +19.0% |
| Debt/Equity | 1.27 | 1.35 | 1.37 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |